Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 8/20 | 1.00 |
| ▸ | NR4A1 | P22736 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 0.78 |
| ▸ | MEN1 | O00255 | 4/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.78 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.78 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.78 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.78 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.78 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.78 |
| ▸ | RELA | Q04206 | 1/20 | 0.78 |
| ▸ | MBD2 | Q9UBB5 | 2/20 | 0.74 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.72 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.70 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.68 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.68 |
| ▸ | NPC1 | O15118 | 3/20 | 0.65 |
| ▸ | RAB9A | P51151 | 3/20 | 0.65 |
| ▸ | HTT | P42858 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12298002 | 0.89 | VCP (0.81) | VCPNR4A1MAPTMEN1KMT2A | |
| SCHEMBL12639826 | 0.88 | SMN1; SMN2 (1.00) | VCPNR4A1MAPTMEN1KMT2A | |
| SCHEMBL13803792 | 0.86 | MAPT (0.78) | VCPNR4A1MAPTMEN1KMT2A | |
| SCHEMBL30060152 | 0.85 | MBD2 (1.00) | VCPNR4A1MAPTMEN1KMT2A | |
| SCHEMBL13390238 | 0.85 | MBD2 (1.00) | VCPNR4A1MAPTMEN1KMT2A | |
| SCHEMBL7678939 | 0.85 | MAPT (0.81) | VCPNR4A1MAPTMEN1KMT2A | |
| Bromide SCHEMBL7673197 | 0.83 | MAPT (0.79) | VCPNR4A1MAPTMEN1KMT2A | |
| SCHEMBL23657798 | 0.82 | MAPT (0.72) | VCPNR4A1MAPTMEN1KMT2A | |
| SCHEMBL31126464 | 0.82 | NPY5R (1.00) | VCPNR4A1MAPTMEN1KMT2A | |
| SCHEMBL29601468 | 0.82 | SLC2A1 (0.73) | VCPNR4A1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105436-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-05-05 | — | — | US | claimed |
| US-20110105436-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-05-05 | — | — | US | disclosed |
| US-20110105436-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-05-05 | — | — | US | disclosed |
| US-20110105436-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-05-05 | — | — | US | disclosed |
| WO-2009114552-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009114552-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2009-09-17 | — | — | WO | disclosed |
| US-20090118135-A1 | METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS | THE BURNHAM INSTITUTE (US) | 2009-05-07 | — | — | US | disclosed |
| US-20090118135-A1 | METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS | THE BURNHAM INSTITUTE (US) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105436-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT | VHL, TP53, BECN1 | VCP 137/4885NR4A1 3329/4885MAPT 2506/4885 |
| US-20090118135-A1 | METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS | BCL2, BAX, BAD | VCP 2182/4885NR4A1 4082/4885MAPT 3866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.